Skip to main content

Advertisement

SpringerLink
Log in

Safety of zoledronate in older patients at high risk of fracture with reduced renal function

  • Letter to the Editor
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. EMC zoledronic acid 5 mg solution for infusion. https://www.medicines.org.uk/emc/medicine/28527#gref. Accessed 6 March 2022

  2. Naganathar N, Yau W, Mok ZH, Tan ZYF, Chew STH (2021) Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice. Osteoporos Int 32(10):1981–1988. https://doi.org/10.1007/s00198-021-05907-5

    Article  CAS  PubMed  Google Scholar 

  3. Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, Eastell R, Walsh JS (2022) Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int 33(3):737–744. https://doi.org/10.1007/s00198-021-06160-6

    Article  CAS  PubMed  Google Scholar 

  4. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical School, George Davies Centre, University of Leicester, Lancaster Rd, Leicester, UK

    A. Sahota

  2. East Bridgford Medical Centre, Nottinghamshire Healthcare, Nottingham, UK

    R. Barbary & A.-M. Stewart

  3. Depart HCOP, Nottingham University Hospitals NHS Trust, Nottingham, UK

    M. Cameron & O. Sahota

  4. The Centre for Spinal Studies and Surgery, Nottingham University Hospital NHS Trust, Nottingham, UK

    O. Sahota

  5. Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, UK

    O. Sahota

  6. National Institute for Health Research (NIHR), Nottingham Biomedical Research Centre (BRC), University of Nottingham, Nottingham, UK

    O. Sahota

Authors
  1. A. Sahota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Barbary
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A.-M. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Sahota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Sahota.

Ethics declarations

Conflicts of interest

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sahota, A., Barbary, R., Cameron, M. et al. Safety of zoledronate in older patients at high risk of fracture with reduced renal function. Osteoporos Int 33, 1823–1824 (2022). https://doi.org/10.1007/s00198-022-06427-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-022-06427-6

Search

Navigation